Somanathapura K. NaveenKumar

Somanathapura K. NaveenKumar

Auto-generated profile, based on publicly available information

Somanathapura K. NaveenKumar

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Science Advances
Verified
Journal Article
Open access
CLChao Liu
Chao Liu
SYSrilakshmi Yalavarthi
Srilakshmi Yalavarthi
ATAjay Tambralli
Ajay Tambralli
LZLixia Zeng
Lixia Zeng
CRChristine E. Rysenga
Christine E. Rysenga
JKJason Knight
Jason Knight
While neutrophil extracellular traps (NETs) have previously been linked to some diabetes-associated complications, such as dysfunctional wound healing, their potential role in diabetic vascular dysfunction has not been studied. Diabetic Akita mice were crossed with either Elane −/− or Pad4 −/− mice to generate NET-deficient diabetic mice. By 24 weeks of age, Akita aortae showed markedly impaired relaxation in response to acetylcholine, indicative of vascular dysfunction. Both Akita- Elane −/− mice and Akita- Pad4 −/− mice had reduced levels of circulating NETs and improved acetylcholine-mediated aortic relaxation. Compared with wild-type aortae, the thromboxane metabolite TXB 2 was roughly 10-fold higher in both intact and endothelium-denuded aortae of Akita mice. In contrast, Akita- Elane −/− and Akita- Pad4 −/− aortae had TXB 2 levels similar to wild type. In summary, inhibition of NETosis by two independent strategies prevented the development of vascular dysfunction in diabetic Akita mice. Thromboxane was up-regulated in the vessel walls of NETosis-competent diabetic mice, suggesting a role for neutrophils in driving the production of this vasoconstrictive and atherogenic prostanoid.

21 March 2024 in Blood
Verified
Journal Article
Closed access
PDF file
SNSomanathapura K. NaveenKumar
Somanathapura K. NaveenKumar
ATAjay Tambralli
Ajay Tambralli
BFBruna Mazetto Fonseca
Bruna Mazetto Fonseca
SYSrilakshmi Yalavarthi
Srilakshmi Yalavarthi
WLWenying Liang
Wenying Liang
JKJason Knight
Jason Knight
Many patients with antiphospholipid syndrome had decreased ectonucleotidase activity on neutrophils and platelets, which enabled extracellular nucleotides to trigger neutrophil-platelet aggregates. This phenotype was replicated by treating healthy neutrophils and platelets with patient-derived antiphospholipid antibodies or ectonucleotidase inhibitors.

29 October 2025 in Blood Advances
Verified
Journal Article
Open access
SNSomanathapura K. NaveenKumar
Somanathapura K. NaveenKumar
TNThalia G. Newman
Thalia G. Newman
BFBruna Mazetto Fonseca
Bruna Mazetto Fonseca
SYSrilakshmi Yalavarthi
Srilakshmi Yalavarthi
MNMariane C. Flores Nascimento
Mariane C. Flores Nascimento
JKJason Knight
Jason Knight
Platelet activation is a hallmark of antiphospholipid syndrome (APS). However, the mechanisms through which antiphospholipid antibodies activate platelets and the optimal way to inhibit this pathophysiology are still not fully understood. Extracellular adenosine, produced by the ectoenzyme CD73, activates cell-surface receptors to increase intracellular cyclic adenosine monophosphate (cAMP), raising the threshold for platelet activation. Here, we found that platelets from patients with APS exhibited lower CD73 activity and cAMP content than healthy controls. Platelet activation, as measured by the surface expression of CD62P and activated αIIbβ3, was negatively correlated with CD73 activity and cAMP content. Exposing healthy platelets to APS patient immunoglobulin G (IgG) in vitro significantly reduced CD73 activity and intracellular cAMP while simultaneously increasing activation markers. We identified critical roles for FcγRIIa, phospholipase C, and the Akt signaling pathway in platelet activation by APS IgG. We also tested whether various agents that boost intracellular cAMP could blunt APS IgG–induced platelet activation. Agonism of the adenosine 2A receptor (A2AR) and inhibition of phosphodiesterase 3 (PDE3) were both highly effective in this regard. In summary, a dysregulated adenosinergic axis appears to potentiate APS platelets for prothrombotic activation by antiphospholipid antibodies. A2AR agonists and PDE3 inhibitors may be useful strategies for restoring platelet homeostasis in APS.

29 January 2026 in Arthritis & Rheumatology
Verified
Journal Article
Open access
BFBruna de Moraes Mazetto Fonseca
Bruna de Moraes Mazetto Fonseca
SNSomanathapura K. NaveenKumar
Somanathapura K. NaveenKumar
SYSrilakshmi Yalavarthi
Srilakshmi Yalavarthi
KSKavya Sugur
Kavya Sugur
TNThalia G. Newman
Thalia G. Newman
JKJason Knight
Jason Knight
Objective: ATP is released from platelets through both degranulation and pannexin‐1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium‐dependent signaling. The objective of this study was to evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired thromboinflammatory disorder characterized by platelet‐activating antiphospholipid antibodies. Methods: Extracellular ATP release was measured in platelets isolated from patients with persistently positive antiphospholipid antibodies (n = 36), patients with systemic lupus erythematosus (n = 10), and healthy controls (n = 16). In some assays, purified platelets were pretreated with the PANX inhibitor carbenoxolone. Platelet signaling, P‐selectin exposure, and aggregation were assessed. Results: Basal ATP release was significantly higher in APS platelets than in controls ( P < 0.0001) and normalized in the presence of carbenoxolone ( P = 0.03). Carbenoxolone also reduced platelet ATP release and surface P‐selectin expression induced by thrombin ( P = 0.002 and P = 0.02, respectively) and convulxin ( P = 0.0001 and P = 0.0012). Control platelets stimulated with IgG from patients with APS demonstrated enhanced phosphorylation of PANX1 at tyrosine‐308 ( P = 0.03), which was accompanied by enhanced ATP release ( P = 0.0004). APS IgG boosted ADP‐induced aggregation ( P = 0.0011), which was reduced by carbenoxolone ( P = 0.0007). The calcium chelator BAPTA‐AM decreased APS IgG–mediated ATP release ( P = 0.03), P‐selectin expression ( P = 0.0005), and aggregation ( P = 0.0007). Desensitizing P2X1 receptors with α,β‐MeATP decreased APS IgG–induced P‐selectin expression ( P = 0.0002) and aggregation ( P = 0.01). Conclusion: PANX1 channels appear to be important mediators of platelet activation in APS. Agents that block PANX1 may restore platelet homeostasis and limit thrombosis without impairing hemostasis. image